Abstract:Background: Nasopharyngeal carcinoma (NPC), arising from nasopharynx epithelium, is a rare type of malignant carcinoma that has a specific geographical distribution and a high risk of distant metastases. For most of the diagnosed NPC patients, the total survival rate decreased significantly due to the high local recurrence rate and metastasis rate. Concurrent chemoradiotherapy (CCRT), as routine therapy strategy of NPC, usually accompanies with high-dosage cytotoxic agents and serious toxic side reaction. Therefore, there is an urgent need for update the existing therapy strategies. In this study, we sought to investigate the effects of a combined therapy strategy, erlotinib combined with cisplatin and radiotherapy, on biological characteristics of NPC CNE2 cells and the potential reasons. Methods: CNE2 cells in logarithmic phase seeding in 96-well plates received concentration gradients of erlotinib (at 0, 10, 20, 40, 80, 160, 320 mmol/L) or cisplatin (at 0, 0.25, 0.5, 1, 2, 4, 8 mg/L), in order to obtain the optimal working concentration of erlotinib and cisplatin via 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Then, cells were divided into control group and four treatment groups (Group I-IV). All treatment groups received irradiation of 4 Gy, moreover, Group II-IV respectively received erlotinib, cisplatin and erlotinib plus cisplatin at optimal working concentration. After 24 and 48 h of irradiation, growth inhibition rate was determined; invasion ability and migration ability was respectively detected by Boyden's chamber assay and cell scratch test; flow cytometry was performed for determining apoptosis rate and cell cycle distribution; the expression levels of epidermal growth factor receptor (EGFR) signal pathway proteins were semi-quantitatively analyzed by Western-blot. Results: Compared with Group I, all the other treatment groups showed better inhibition effect on cell viability, invasion and migration ability and higher apoptosis rate, while Group IV showed the strongest growth inhibition effect and highest apoptosis rate. In addition, EGFR signal pathway proteins of Group IV showed the lowest expression level. Conclusions: In combined therapy with radiotherapy/chemotherapy, erlotinib could enhance radiotherapy/chemotherapy sensitivity, probably because it could suppress DNA damage repair after radiotherapy/chemotherapy, thus weakening radiotherapy/chemotherapy resistance of tumor cells.

ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma

Identification of Prognostic Biomarkers for Response to Radiotherapy by DNA Microarray in Nasopharyngeal Carcinoma Patients

Induction of Cell Cycle Arrest and Apoptosis in Human Nasopharyngeal Carcinoma Cells by ZD6474, an Inhibitor of VEGFR Tyrosine Kinase with Additional Activity Against EGFR Tyrosine Kinase

A Low Dose of AZD8055 Enhances Radiosensitivity of Nasopharyngeal Carcinoma Cells by Activating Autophagy and Apoptosis

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

Inhibition of MNK pathway sensitizes nasopharyngeal carcinoma to radiotherapy

Met Inhibitor Pha-665752 Suppresses the Hepatocyte Growth Factor-Induced Cell Proliferation and Radioresistance in Nasopharyngeal Carcinoma Cells

ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.

Dual Phosphoinositide 3-Kinase/mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.

MicroRNA-372 Enhances Radiosensitivity While Inhibiting Cell Invasion and Metastasis in Nasopharyngeal Carcinoma Through Activating the PBK-dependent P53 Signaling Pathway

Inhibition of ZIP4 Reverses Epithelial-to-mesenchymal Transition and Enhances the Radiosensitivity in Human Nasopharyngeal Carcinoma Cells

Enhanced therapeutic efficacy of adenovirus-mediated interleukin-24 gene therapy combined with ionizing radiotherapy for nasopharyngeal carcinoma

Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer.

Antitumor and Radiosensitization Effects of a CXCR2 Inhibitor in Nasopharyngeal Carcinoma

Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism

Metformin Inhibits-The Growth-Of Nasopharyngeal Carcinoma Cells and Sensitizes the Cells to Radiation Via Inhibition of the Dna Damage Repair Pathway

Antitumor and Radiosensitizing Effects of SKLB-163, a Novel Benzothiazole-2-thiol Derivative, on Nasopharyngeal Carcinoma by Affecting the RhoGDI/JNK-1 Signaling Pathway.

Inhibition of Aurora-A Results in Increased Cell Death in 3-Dimensional Culture Microenvironment, Reduced Migration and is Associated with Enhanced Radiosensitivity in Human Nasopharyngeal Carcinoma

Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells

Supplemental Figures S1-S7 from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Enhanced radiosensitivity and chemoradiation efficacy in nasopharyngeal carcinoma via a dual-targeted SPION@polymer hybrid nanosensitizer